Phenotypic variation in familial melanoma: Consequences for predictive DNA testing

Archives of Dermatology

Volumn 143, Issue 4, 2007, Pages 525-526

  Bergman, Wilma ^a   Gruis, Nelleke A ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; MELANOCORTIN 1 RECEPTOR;

CANCER RISK; CARCINOMA IN SITU; DISEASE PREDISPOSITION; DNA DETERMINATION; EDITORIAL; FAMILY HISTORY; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HAPLOTYPE; HODGKIN DISEASE; HUMAN; MELANOMA; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; GERMANY; HODGKIN DISEASE; HUMANS; MELANOMA; NEOPLASMS, MULTIPLE PRIMARY; NETHERLANDS; OVARIAN NEOPLASMS; PHENOTYPE; RECEPTOR, MELANOCORTIN, TYPE 1; SKIN NEOPLASMS;

EID: 34247356864     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.4.525     Document Type: Editorial

References (15)

1. Figl A, Thirumaran RK, Ugurel S, et al. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. Arch Dermatol. 2007;143:495-499.
2. Hille ET, van Duijn E, Gruis NA, Rosendaal FR, Bergman W, VandenBroucke JP. Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1940. J Invest Dermatol. 1998;110:788-792.
3. Vasen HF, Gruis NA, Frants RR, van der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma syndrome associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87:809-811.
4. Laud K, Kannengiesser C, Avril MF, et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res. 2003;63:3061-3065.
5. Lang J, Boxer M, MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat. 2003;21:327-330.
6. van der Velden PA, Sandkuijl LA, Bergman W, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet. 2001;69:774-779.
7. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet. 2001;69:765-773.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
9. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res. 1995;5:169-177.
10. Lynch HT, Brand RE, Hogg D, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinomaprone families. Cancer. 2002;94:84-96.
11. Meiser B, Gleeson MA, Tucker KM. Psychological impact of genetic testing for adult-onset disorders: an update for clinicians. Med J Aust. 2000;172:126-129.
12. Riedijk SR, de Snoo FA, van Dijk S, et al. Hereditary melanoma and predictive genetic testing: why not? Psychooncology. 2005;14:738-745.
13. de Snoo FA, Bergman W, Gruis NA. Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam Cancer. 2003;2:109-116.
14. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA; Melanoma Genetics Consortium. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol. 1999;17:3245-3251.
15. van der Velden PA, Sandkuijl LA, Bergman W, Hille ET, Frants RR, Gruis NA. A Locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. Genome Res. 1999;9:575-578.